Association Between ABO Blood Types and the Side Effects of the First and Second Doses of COVID-19 Vaccination: a Cross-Sectional Study at Shahid Beheshti University of Medical Sciences
SOREN Student Sports & Health Open Researches e-Journal: New-Approaches,
Vol. 3 No. 2 (1401),
1 August 2022
https://doi.org/10.22037/soren.v3i2.42873
Abstract
Background and aim: The rapid global spread of the new SARS-CoV-2 coronavirus strained healthcare resources and caused the rapid introduction of Covid-19 vaccines to combat this virus. Due to this rapid launch and development, it is necessary to monitor complications after vaccination. On the other hand, it has been observed that the ABO blood group may affect the side effects experienced by people who receive the COVID-19 vaccine. This aim of study was association between blood types and the side effects of three types of COVID-19 vaccines (Sputnik, AstraZeneca, and Sinopharm).
Methods: This research was cross-sectional. The research population includes 420 employees of Shahid Beheshti University of Medical Sciences in Tehran, who received both doses of the COVID-19 vaccine. The association between blood group and symptoms related to the vaccination of COVID-19 after doses 1 and 2 was analyzed with SPSS version 23 software at a significance level of 0.05.
Results: Most of the study participants were male (58.7%). 18.6% were vaccinated with Sputnik vaccine, 75.1% with Sinopharm and 6.3% with AstraZeneca. The results of the research showed that there was no statistically significant relationship between blood groups and side effects of the first and second doses of vaccination for any of the studied vaccines.
Conclusion: COVID-19 vaccination may cause reactions and symptoms. However, ABO blood types do not seem to be a predictor of vaccine reactivity and there was no significant relationship between blood groups and the prevalence of symptoms.
- Blood Types ▪ COVID-19 ▪ Shahid Beheshti University of Medical Sciences ▪ Side Effects ▪ Coronavirus
How to Cite
References
2. WHO.int.Coronavirus disease (COVID-19) situation dashboard 2020. Available from: https://covid19.who.int/. Acssessed March 2, 2021.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382(13):1199-1207.
4. Schaffer Deroo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA 2020;323(24):2458–9.
5. Plotkin S. History of vaccination. Proc Natl Acad Sci USA 2014;111(34):12283-7.
6. Maserat E, Keikha L, Davoodi S, Mohammadzadeh Z. E-health roadmap for COVID-19 vaccine coverage in Iran. BMC public health 2021;21(1).
7. Meysamie A, Ghasemi E, Moshksar S, Askarian M. Intention to receive COVID-19 vaccine among healthcare workers: a comparison between two surveys. BMC Health Services Research 2022;22(1):1-1.
8. COVID-19 therapies and vaccine landscape. Nat Mater 2020;19(8):809.
9. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021;397(10275):642–3.
10. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020;396(10267):1979–93.
11. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 2020;182(3):713-721.
12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
13. Askarian M, Fu L, Taghrir MH, Borazjani R, Shayan Z, Taherifard E, et al. Factors affecting COVID-19 vaccination intent among Iranians: COVID-19 vaccination acceptance. 2020.
14. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathologia Persa 2021;7(2).
15. Yamamoto F, Cid E, Yamamoto M, Blancher A. ABO research in the modern era of genomics. Transfus Med Rev 2012;26(2):103-18.
16. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PKS, Ng MHL, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293(12):1447–1451.
17. Takagi H. Down the Rabbit‐Hole of blood groups and COVID‐19. B J Haem 2020;190:268-270.
18. Boudin L, Janvier F, Bylicki O, Dutasta F. ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults. Haematologica 2020;105(12): 2841-2843.
- Abstract Viewed: 418 times
- PDF (فارسی) Downloaded: 199 times